Sphingosine Kinases Promote IL-17 Expression in Human T Lymphocytes

Overview

Journal Sci Rep

Specialty Science

Date 2018 Sep 7

PMID 30185808

Citations 11

Authors

Giusi Barra

Alessio Lepore

Miriam Gagliardi

Domenico Somma

Maria Rosaria Matarazzo

Francesca Costabile

Giuseppe Pasquale

Alessio Mazzoni

Carmela Gallo

Genoveffa Nuzzo

Francesco Annunziato

Angelo Fontana

Antonio Leonardi

Raffaele De Palma

Affiliations

Soon will be listed here.

Abstract

Sphingosine 1-phosphate (S1P) has a role in many cellular processes. S1P is involved in cell growth and apoptosis, regulation of cell trafficking, production of cytokines and chemokines. The kinases SphK1 and SphK2 (SphKs) phosphorilate Sphingosine (Sph) to S1P and several phosphatases revert S1P to sphingosine, thus assuring a balanced pool that can be depleted by a Sphingosine lyase in hexadecenal compounds and aldehydes. There are evidences that SphK1 and 2 may per se control cellular processes. Here, we report that Sph kinases regulate IL-17 expression in human T cells. SphKs inhibition impairs the production of IL-17, while their overexpression up-regulates expression of the cytokine through acetylation of IL-17 promoter. SphKs were up-regulated also in PBMCs of patients affected by IL-17 related diseases. Thus, S1P/S1P kinases axis is a mechanism likely to promote IL-17 expression in human T cells, representing a possible therapeutic target in human inflammatory diseases.

Citing Articles

Sphingolipid biosynthesis is essential for metabolic rewiring during T17 cell differentiation.

Abimannan T, Parthibane V, Le S, Vijaykrishna N, Fox S, Karim B Sci Adv. 2024; 10(17):eadk1045.

PMID: 38657065 PMC: 11042737. DOI: 10.1126/sciadv.adk1045.

The Role of hsa-miR-125b-5p Interaction with S1P/Ceramide Axis in the Potential Development of Inflammation-Associated Colon Cancer in Primary Sclerosing Cholangitis.

Abramczyk J, Milkiewicz M, Hula B, Milkiewicz P, Kempinska-Podhorodecka A Int J Mol Sci. 2023; 24(11).

PMID: 37298127 PMC: 10252877. DOI: 10.3390/ijms24119175.

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia.

Sarapura Martinez V, Buonincontro B, Cassarino C, Bernatowiez J, Colado A, Cordini G Front Oncol. 2023; 13:1143881.

PMID: 37020867 PMC: 10067719. DOI: 10.3389/fonc.2023.1143881.

Chlamydia trachomatis L2/434/Bu Favors Hypoxia for its Growth in Human Lymphoid Jurkat Cells While Maintaining Production of Proinflammatory Cytokines.

Tsujikawa R, Thapa J, Okubo T, Nakamura S, Zhang S, Furuta Y Curr Microbiol. 2022; 79(9):265.

PMID: 35859064 DOI: 10.1007/s00284-022-02961-y.

Pharmacological Targeting of Sphingosine Kinases Impedes HIV-1 Infection of CD4 T Cells through SAMHD1 Modulation.

Resop R, Bosque A J Virol. 2022; 96(9):e0009622.

PMID: 35412343 PMC: 9093127. DOI: 10.1128/jvi.00096-22.

References

Kunkel G, Maceyka M, Milstien S, Spiegel S . Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013; 12(9):688-702. PMC: 3908769. DOI: 10.1038/nrd4099. View

Cyster J, Schwab S . Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol. 2011; 30:69-94. DOI: 10.1146/annurev-immunol-020711-075011. View

Roviezzo F, Di Lorenzo A, Bucci M, Brancaleone V, Vellecco V, De Nardo M . Sphingosine-1-phosphate/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness. Am J Respir Cell Mol Biol. 2007; 36(6):757-62. DOI: 10.1165/rcmb.2006-0383OC. View

Bailey S, Nelson M, Himes R, Li Z, Mehrotra S, Paulos C . Th17 cells in cancer: the ultimate identity crisis. Front Immunol. 2014; 5:276. PMC: 4060300. DOI: 10.3389/fimmu.2014.00276. View

Maceyka M, Milstien S, Spiegel S . Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling. J Lipid Res. 2008; 50 Suppl:S272-6. PMC: 2674705. DOI: 10.1194/jlr.R800065-JLR200. View

Santarlasci V, Maggi L, Capone M, Querci V, Beltrame L, Cavalieri D . Rarity of human T helper 17 cells is due to retinoic acid orphan receptor-dependent mechanisms that limit their expansion. Immunity. 2012; 36(2):201-14. DOI: 10.1016/j.immuni.2011.12.013. View

French K, Upson J, Keller S, Zhuang Y, Yun J, Smith C . Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006; 318(2):596-603. DOI: 10.1124/jpet.106.101345. View

Degtyar E, Zusman T, Ehrlich M, Segal G . A Legionella effector acquired from protozoa is involved in sphingolipids metabolism and is targeted to the host cell mitochondria. Cell Microbiol. 2009; 11(8):1219-35. DOI: 10.1111/j.1462-5822.2009.01328.x. View

Hait N, Allegood J, Maceyka M, Strub G, Harikumar K, Singh S . Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009; 325(5945):1254-7. PMC: 2850596. DOI: 10.1126/science.1176709. View

10.

Proia R, Hla T . Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015; 125(4):1379-87. PMC: 4409021. DOI: 10.1172/JCI76369. View

11.

Cutignano A, Nuzzo G, Ianora A, Luongo E, Romano G, Gallo C . Development and Application of a Novel SPE-Method for Bioassay-Guided Fractionation of Marine Extracts. Mar Drugs. 2015; 13(9):5736-49. PMC: 4584351. DOI: 10.3390/md13095736. View

12.

Spiegel S, Milstien S . The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011; 11(6):403-15. PMC: 3368251. DOI: 10.1038/nri2974. View

13.

Liang J, Nagahashi M, Kim E, Harikumar K, Yamada A, Huang W . Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013; 23(1):107-20. PMC: 3578577. DOI: 10.1016/j.ccr.2012.11.013. View

14.

Korn T, Bettelli E, Oukka M, Kuchroo V . IL-17 and Th17 Cells. Annu Rev Immunol. 2009; 27:485-517. DOI: 10.1146/annurev.immunol.021908.132710. View

15.

Gatto S, Gagliardi M, Franzese M, Leppert S, Papa M, Cammisa M . ICF-specific DNMT3B dysfunction interferes with intragenic regulation of mRNA transcription and alternative splicing. Nucleic Acids Res. 2017; 45(10):5739-5756. PMC: 5449610. DOI: 10.1093/nar/gkx163. View

16.

Plano D, Amin S, Sharma A . Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. J Med Chem. 2014; 57(13):5509-24. DOI: 10.1021/jm4011687. View

17.

Garris C, Wu L, Acharya S, Arac A, Blaho V, Huang Y . Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol. 2013; 14(11):1166-72. PMC: 4014310. DOI: 10.1038/ni.2730. View

18.

Aguilar A, Saba J . Truth and consequences of sphingosine-1-phosphate lyase. Adv Biol Regul. 2013; 52(1):17-30. PMC: 3560305. DOI: 10.1016/j.advenzreg.2011.09.015. View

19.

Fang V, Chaluvadi V, Ramos-Perez W, Mendoza A, Baeyens A, Rivera R . Gradients of the signaling lipid S1P in lymph nodes position natural killer cells and regulate their interferon-γ response. Nat Immunol. 2016; 18(1):15-25. PMC: 5675020. DOI: 10.1038/ni.3619. View

20.

Wilson N, Boniface K, Chan J, McKenzie B, Blumenschein W, Mattson J . Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007; 8(9):950-7. DOI: 10.1038/ni1497. View